Last reviewed · How we verify
ESTRAMUSTINE PHOSPHATE SODIUM
Estramustine Phosphate Sodium is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | ESTRAMUSTINE PHOSPHATE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
Key clinical trials
- Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
- Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer (PHASE2)
- Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (PHASE3)
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer (PHASE3)
- Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESTRAMUSTINE PHOSPHATE SODIUM CI brief — competitive landscape report
- ESTRAMUSTINE PHOSPHATE SODIUM updates RSS · CI watch RSS